Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2015 Jun 5;5(1):e1058459. doi: 10.1080/2162402X.2015.1058459

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© Taylor & Francis Group, LLC

PMC Copyright notice

Figure 3. — Enhanced killing of patients' tumor cells by combinations of rituximab and the immunoligands. (A) Both ULBP2:7D8 (left panel) and B7-H6:7D8 (right panel) increased rituximab-mediated ADCC against freshly isolated CLL cells (CLL p #1; ++++, CI = 0.1 − 0.3; +++, CI = 0.3 – 0.7). (B) Illustration of synergistic effects at the 25% effect level by isobolograms. (C) Cytotoxicity induced by varying concentrations of rituximab alone or in combination with either ULBP2:7D8 or B7-H6:7D8 against a panel of tumor cell samples. NK cells from healthy donors were applied as effector cells (E:T cell ratio = 20:1). Data are presented as mean percentage of lysis from triplicate determinations. Data acquired with different tumor samples were analyzed in a summary graph for statistical analysis. (* and # indicate statistical significant differences between rituximab as single agent or combined with either ULBP2:7D8 or B7-H6:7D8, respectively. p, patient).